






**INTERNALLY FUNDED**

**EXTERNALLY FUNDED**

PRODUCT	INDICATION	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	PARTNER/COLLABORATOR/FUNDER
---------	------------	--------------	---------	---------	---------	-----------------------------







**HPV-TARGETED**

VGX-3100	Cervical Dysplasia (HSIL)					 <b>Apollobio</b> (China; INOVIO maintains global rights)
	Vulvar Dysplasia (HSIL)					
	Anal Dysplasia (HSIL)					
INO-3107	Recurrent Respiratory Papillomatosis (RRP)					





**IMMUNO-ONCOLOGY**

INO-5401	Glioblastoma (GBM)					<b>REGENERON</b>
----------	--------------------	--	--	--	--	------------------

**INFECTIOUS DISEASES**

INO-4800	COVID-19 (Solidarity)					
INO-4201	Ebola (Booster)					  

**dMAb™**

	COVID-19					  
INO-A002	Zika	